We are proud to announce a major step forward in the development of ATL-001, our oral candidate for the treatment of Congenital Erythropoietic Porphyria: the first three patients with CEP have recently been enrolled in our Phase 1/2 clinical trial.
We would like to express our sincere gratitude to Dr. Angelika Erwin and the team at Cleveland Clinic for their dedication, commitment, and continuous support for patients with CEP. Their involvement and effort are essential to advancing this research and helping bring patients closer to a much-needed therapeutic option for this rare and impactful disease.
We continue to work with determination and hope, together with our investigators, collaborators, and the patient community, to bring new solutions to those who need them most.